

<i>Contributors</i>	vii
<i>Preface</i>	xxv
<i>Acknowledgments</i>	xxvii

PART I

Principles of Oncology

1. The Cancer Genome	2
<i>Yardena Samuels, Alberto Bardelli, Jared J. Gartner, and Carlos López-Otin</i>	
Introduction	2
Cancer Genes and Their Mutations	2
Identification of Cancer Genes	2
Somatic Alteration Classes Detected by Cancer Genome Analysis	10
Pathway-Oriented Models of Cancer Genome Analysis	11
Networks of Cancer Genome Projects	13
The Genomic Landscape of Cancers	15
Integrative Analysis of Cancer Genomics	16
The Cancer Genome and the New Taxonomy of Tumors	16
Cancer Genomics and Drug Resistance	19
Perspectives of Cancer Genome Analysis	20
Acknowledgments	20
2. Hallmarks of Cancer: An Organizing Principle for Cancer Medicine	24
<i>Douglas Hanahan and Robert A. Weinberg</i>	
Introduction	24
Hallmark Capabilities, in Essence	24
Two Ubiquitous Characteristics Facilitate the Acquisition of Hallmark Capabilities	33
The Constituent Cell Types of the Tumor Microenvironment	35
Therapeutic Targeting of the Hallmarks of Cancer	41
Conclusion and a Vision for the Future	42
Acknowledgment	43
3. Molecular Methods in Cancer	45
<i>Larissa V. Furtado, Jay L. Hess, and Bryan L. Betz</i>	
Applications of Molecular Diagnostics in Oncology	45
The Clinical Molecular Diagnostics Laboratory: Rules and Regulations	48
Specimen Requirements for Molecular Diagnostics	49
Molecular Diagnostics Testing Process	49
Technologies	50

PART II

Etiology and Epidemiology of Cancer

SECTION 1. ETIOLOGY OF CANCER

4. Tobacco	62
<i>Richard J. O'Connor</i>	
Introduction	62
Epidemiology of Tobacco and Cancer	62
Carcinogens in Tobacco Products and Processes of Cancer Development	64
5. Oncogenic Viruses	69
<i>Christopher B. Buck and Lee Ratner</i>	
Principles of Tumor Virology	69
Papillomaviruses	71
Polyomaviruses	73
Epstein-Barr Virus	74
Kaposi's Sarcoma Herpesvirus	75
Animal and Human Retroviruses	77
Hepatitis Viruses	79
Conclusion	81
6. Inflammation	83
<i>Sahdeo Prasad and Bharat B. Aggarwal</i>	
Introduction	83
Molecular Basis of Inflammation	83
Role of Inflammation in Transformation	83
Role of Inflammation in Survival	84
Role of Inflammation in Proliferation	85
Role of Inflammation in Invasion	85
Role of Inflammation in Angiogenesis	85
Role of Inflammation in Metastasis	86
Epigenetic Changes and Inflammation	86
Role of Inflammation in Cancer Diagnosis	87
Inflammation and Genomics	87
Inflammation and Targeted Therapies	87
Conclusions	87
7. Chemical Factors	89
<i>Stuart H. Yuspa and Peter G. Shields</i>	
Introduction	89
The Nature of Chemical Carcinogens: Chemistry and Metabolism	89
Animal Model Systems and Chemical Carcinogenesis	90
Molecular Epidemiology, Chemical Carcinogenesis, and Cancer Risk in Human Populations	91
Aristolochic Acid and Urothelial Cancers as a Model for Identifying Human Carcinogens	92

8. Physical Factors 95*Mats Ljungman*

- Introduction 95
- Ionizing Radiation 95
- Ultraviolet Light 98
- Radiofrequency and Microwave Radiation 99
- Electromagnetic Fields 100
- Asbestos 100
- Nanoparticles 101

9. Dietary Factors 103*Karin B. Michels and Walter C. Willett*

- Introduction 103
- Methodologic Challenges 103
- The Role of Individual Food and Nutrients in Cancer Etiology 104
- Other Foods and Nutrients 108
- Dietary Patterns 110
- Diet During the Early Phases of Life 110
- Diet after a Diagnosis of Cancer 110
- Summary 111
- Limitations 111
- Future Directions 112
- Recommendations 112

10. Obesity and Physical Activity 114*Yani Lu, Jessica Clague, and Leslie Bernstein*

- Introduction 114
- Breast Cancer 114
- Colon and Rectal Cancer 115
- Endometrial Cancer 116
- Adenocarcinoma of the Esophagus 117
- Kidney/Renal Cell Cancer 117
- Pancreatic Cancer 117
- Gallbladder Cancer 117
- Non-Hodgkin Lymphoma 117
- Prostate Cancer 117
- Lung Cancer 118
- Ovarian Cancer 118
- Conclusions 118

SECTION 2. EPIDEMIOLOGY OF CANCER**11. Epidemiologic Methods 120***Xiaomei Ma and Herbert Yu*

- Introduction 120
- Analytical Studies 120
- Interpretation of Epidemiologic Findings 123
- Cancer Outcomes Research 123
- Molecular Epidemiology 124

12. Trends in United States Cancer Mortality. . . 128*Tim E. Byers*

- Introduction 128
- Cancer Surveillance Systems 128
- Making Sense of Cancer Trends 128
- Trends in Cancer Risk Factors and Screening 128
- Cancer Incidence and Mortality 128
- Predicting Future Cancer Trends 133

PART III**Cancer Therapeutics****13. Essentials of Radiation Therapy 136***Meredith A. Morgan, Randall K. Ten Haken, and Theodore S. Lawrence*

- Introduction 136
- Biologic Aspects of Radiation Oncology 136
- Factors that Affect Radiation Response 141
- Drugs that Affect Radiation Sensitivity 143
- Radiation Physics 144
- Treatment Planning 148
- Other Treatment Modalities 149
- Clinical Applications of Radiation Therapy 151
- Treatment Intent 152
- Fractionation 153
- Adverse Effects 153
- Principles of Combining Anticancer Agents with Radiation Therapy 155

14. Cancer Immunotherapy 158*Steven A. Rosenberg, Paul F. Robbins, Giao Q. Phan, Steven A. Feldman, and James N. Kochenderfer*

- Introduction 158
- Human Tumor Antigens 158
- Human Cancer Immunotherapies 161

15. Pharmacokinetics and Pharmacodynamics of Anticancer Drugs 174*Alex Sparreboom and Sharyn D. Baker*

- Introduction 174
- Pharmacokinetic Concepts 174
- Pharmacodynamic Concepts 176
- Variability in Pharmacokinetics/Pharmacodynamics 176
- Dose-Adaptation Using Pharmacokinetic/Pharmacodynamic Principles 180

16. Pharmacogenomics 183*Christine M. Walko and Howard L. McLeod*

- Introduction 183
- Pharmacogenomics of Tumor Response 183
- Pharmacogenomics of Chemotherapy Drug Toxicity 186
- Conclusions and Future Directions 188

17. Alkylating Agents 189*Kenneth D. Tew*

- Perspectives 189
- Chemistry 189
- Classification 189
- Clinical Pharmacokinetics/Pharmacodynamics 193
- Therapeutic Uses 194
- Toxicities 195
- Complications with High-Dose Alkylating Agent Therapy 196
- Alkylating Agent–Steroid Conjugates 196
- Drug Resistance and Modulation 197
- Recent Developments 197

18. Platinum Analogs. 199*Peter J. O'Dwyer and A. Hilary Calvert*

Introduction 199

History 199

Platinum Chemistry 199

Platinum Complexes after Cisplatin 199

Mechanism of Action 201

Cellular Responses to Platinum-Induced DNA Damage 201

Is DNA the Only Target? 202

Mechanisms of Resistance 202

Clinical Pharmacology 203

Formulation and Administration 205

Toxicity 205

19. Antimetabolites 208*M. Wasif Saif and Edward Chu*

Antifolates 208

5-Fluoropyrimidines 210

Capecitabine 212

Cytarabine 213

Gemcitabine 214

6-Thiopurines 214

Fludarabine 215

Cladribine 215

Clofarabine 216

20. Topoisomerase Interactive Agents 218*Khanh T. Do, Shivaani Kummar, James H. Doroshow, and Yves Pommier*

Classification, Biochemical, and

Biologic Functions of Topoisomerases 218

Topoisomerase Inhibitors as Interfacial Poisons 218

Topoisomerase I Inhibitors: Camptothecins and Beyond 220

Topoisomerase II Inhibitors: Intercalators and Nonintercalators 223

Therapy-Related Secondary Acute Leukemia 226

Future Directions 226

21. Antimicrotubule Agents. 228*Christopher J. Hoimes and Lyndsay N. Harris*

Microtubules 228

Taxanes 228

Vinca Alkaloids 232

Microtubule Antagonists 234

Mitotic Motor Protein Inhibitors 234

Mechanisms of Resistance to Microtubule Inhibitors 235

22. Kinase Inhibitors as Anticancer Drugs. 237*Charles L. Sawyers*

Introduction 237

Early Successes: Targeting Cancers with

Well-Known Kinase Mutations (BCR-ABL, KIT, HER2) 237

Directly Targeting the PI3K Pathway 245

Combinations of Kinase Inhibitors to

Induct Response and Prevent Resistance 245

Speculations on the Future Role of Kinase Inhibitors in

Cancer Medicine 246

23. Histone Deacetylase Inhibitors and Demethylating Agents. 248*Steven D. Gore, Stephen B. Baylin, and James G. Herman*

Introduction 248

Epigenetic Abnormalities and Gene Expression Changes in Cancer 248

Histone Deacetylase Inhibitors 252

Epigenetic Therapy for Hematologic Malignancies 254

New Approaches to Epigenetic Therapy 256

24. Proteasome Inhibitors. 258*Christopher J. Kirk, Brian B. Tuch, Shirin Arastu-Kapur, and Lawrence H. Boise*

Biochemistry of the Ubiquitin-Proteasome Pathway 258

Proteasome Inhibitors 258

Proteasome Inhibitors in Cancer 259

25. Poly (ADP-ribose) Polymerase Inhibitors. . . 263*Alan Ashworth*

Introduction 263

Cellular DNA Repair Pathways 263

The Development of PARP Inhibitors 263

BRCA1 and BRCA2 Mutations and DNA Repair 263

PARP-1 Inhibition as a Synthetic Lethal Therapeutic

Strategy for the Treatment of BRCA-Deficient Cancers 264

Initial Clinical Results Testing Synthetic Lethality of

PARP Inhibitors and BRCA Mutation 264

The Use of PARP Inhibitors in Sporadic Cancers 265

Mechanisms of Resistance to PARP Inhibitors 265

Prospects 266

26. Miscellaneous Chemotherapeutic Agents. . 267*M. Sitki Copur, Scott Nicholas Gettinger, Sarah B. Goldberg, and Hari A. Deshpande*

Homoharringtonine and Omacetaxine 267

L-Asparaginase 267

Bleomycin 268

Procarbazine 268

Vismodegib 269

Ado-Trastuzumab Emtansine 269

Sirolimus and Temsirolimus 269

Everolimus 270

Thalidomide, Lenalidomide, and Pomalidomide 270

27. Hormonal Agents 278*Matthew P. Goetz, Charles Erlichman, Charles L. Loprinzi, and Manish Kohli*

Introduction 278

Selective Estrogen Receptor Modulators 278

Aromatase Inhibitors 282

Gonadotropin-Releasing Hormone Analogs 284

Gonadotropin-Releasing Hormone Antagonists 285

Antiandrogens 285

Novel Antiandrogens 286

Other Sex Steroid Therapies 286

Other Hormonal Therapies 288

28. Antiangiogenesis Agents 290*Cindy H. Chau and William Douglas Figg, Sr.*

Introduction 290

Understanding the Angiogenic Process 290

Drug Development of Angiogenesis Inhibitors 291

Clinical Utility of Approved Antiangiogenic Agents

in Cancer Therapy 293

Combination Therapies 297

Biomarkers of Antiangiogenic Therapy 297

Resistance to Antiangiogenic Therapy 298

29. Monoclonal Antibodies 300*Hossein Borghaei, Matthew K. Robinson, Gregory P. Adams, and Louis M. Weiner*

Introduction 300
 Immunoglobulin Structure 300
 Modified Antibody-Based Molecules 300
 Factors Regulating Antibody-Based Tumor Targeting 302
 Unconjugated Antibodies 302
 Altering Signal Transduction 303
 Immunoconjugates 303
 Antibodies Approved for Use in Solid Tumors 304
 Antibodies Used in Hematologic Malignancies 305
 Conclusion 306

30. Assessment of Clinical Response 308*Antonio Tito Fojo and Susan E. Bates*

Introduction 308
 Assessing Response 308
 Alternate Response Criteria 311
 Determining Outcome 313

PART IV**Cancer Prevention and Screening****31. Tobacco Use and the Cancer Patient 322***Graham W. Warren, Benjamin A. Toll, Irene M. Tamí-Maury, and Ellen R. Gritz*

Introduction 322
 Neurobiology of Tobacco Dependence 322
 Tobacco Use Prevalence and the Evolution of Tobacco Products 322
 Tobacco Use by the Cancer Patient 323
 The Clinical Effects of Smoking on the Cancer Patient 323
 Addressing Tobacco Use by the Cancer Patient 326
 Future Considerations 332

32. Role of Surgery in Cancer Prevention 335*José G. Guillem, Andrew Berchuck, Jeffrey F. Moley, Jeffrey A. Norton, Sheryl G. A. Gabram-Mendola, and Vanessa W. Hui*

Introduction 335
 Patients at High Risk for Breast Cancer 335
 Hereditary Diffuse Gastric Cancer 337
 Surgical Prophylaxis of Hereditary Ovarian and Endometrial Cancer 339
 Hereditary Endometrial Cancer (Lynch Syndrome) 340
 Gynecologic Cancer Risk in Very Rare Hereditary Cancer Syndromes 341
 Multiple Endocrine Neoplasia Type 2 341
 Familial Adenomatous Polyposis, MYH-Associated Polyposis, and Lynch Syndrome 344

33. Cancer Risk Reducing Agents 350*Dean E. Brenner, Scott M. Lippman, and Susan T. Mayne*

Why Cancer Prevention as a Clinical Oncology Discipline 350
 Defining Cancer Risk-Reducing Agents (Chemoprevention) 350
 Identifying Potential Cancer Risk-Reducing Agents 350

Preclinical Development of Cancer Risk-Reducing Agents 350
 Clinical Development of Cancer Risk-Reducing Agents 352
 Micronutrients 354
 Anti-Inflammatory Drugs 360
 Epigenetic Targeting Agents (Selective Estrogen Receptor Modulators, 5 α -Steroid Reductase Inhibitors, Polyamine Inhibitors) 361
 Signal Transduction Modifiers 364
 Anti-Infectives 366
 Multiagent Approaches to Cancer Risk Reduction 366

34. Cancer Screening 370*Otis W. Brawley and Howard L. Parnes*

Introduction 370
 Performance Characteristics 370
 Assessing Screening Tests and Outcomes 370
 Problems with Randomized Trials 372
 Screening Guidelines and Recommendations 373
 Breast Cancer 373
 Colon Cancer Screening 378
 Other Cancers of the Gastrointestinal Tract 379
 Gynecologic Cancer 380
 Lung Cancer Screening 382
 Prostate Cancer Screening 383
 Skin Cancer Screening 385

35. Genetic Counseling 389*Ellen T. Matloff and Danielle C. Bonadies*

Introduction 389
 Who is a Candidate for Cancer Genetic Counseling? 389
 Components of the Cancer Genetic Counseling Session 390
 Issues in Cancer Genetic Counseling 393
 Recent Advances and Future Directions 395

PART V**Practice of Oncology****36. Design and Analysis of Clinical Trials 398***Richard M. Simon*

Introduction 398
 Phase 1 Clinical Trials 398
 Phase 2 Clinical Trials 400
 Design of Phase 3 Clinical Trials 404
 Factorial Designs 407
 Analysis of Phase 3 Clinical Trials 409
 Reporting Results of Clinical Trials 413
 False Positive Reports in the Literature 413
 Meta-analysis 413

SECTION 1. CANCER OF THE HEAD AND NECK**37. Molecular Biology of Head and Neck Cancers 416***Thomas E. Carey and Mark E. P. Prince*

Introduction 416
 Molecular Mechanisms in Head and Neck Squamous Cell Carcinoma 418
 The Cancer Genome Atlas Project 419
 Cancer Stem Cells 419

38. Cancer of the Head and Neck 422*William M. Mendenhall, John W. Werning, and David G. Pfister*

- Incidence and Etiology 422
- Anatomy and Pathology 422
- Natural History 422
- Diagnosis 423
- Staging 423
- Principles of Treatment for Squamous Cell Carcinoma 424
- Management 424
- NECK 425
- Chemotherapy 427
- General Principles of Combining Modalities 430
- Chemotherapy as Part of Curative Treatment 431
- Follow-Up 436
- ORAL CAVITY 437
- Lip 437
- Floor of the Mouth 438
- Oral Tongue 439
- Buccal Mucosa 441
- Gingiva and Hard Palate (including Retromolar Trigone) 441
- OROPHARYNX 443
- Anatomy 443
- Pathology 443
- Patterns of Spread 443
- Clinical Picture 444
- Staging 444
- Treatment: Base of Tongue 444
- Results of Treatment: Base of Tongue 445
- Follow-Up: Base of Tongue 445
- Complications of Treatment: Base of Tongue 445
- Treatment: Tonsillar Area 445
- Results of Treatment: Tonsillar Area 446
- Complications of Treatment: Tonsillar Area 446
- Surgical Treatment 446
- Treatment: Soft Palate 446
- Results of Treatment: Soft Palate 447
- Complications of Treatment: Soft Palate 447
- LARYNX 447
- Anatomy 447
- Pathology 447
- Patterns of Spread 447
- Clinical Picture 448
- Differential Diagnosis and Staging 448
- Treatment: Vocal Cord Carcinoma 449
- Treatment: Supraglottic Larynx Carcinoma 449
- Treatment: Subglottic Larynx Carcinoma 450
- Treatment: Supraglottic Larynx Cancer 450
- HYPOPHARYNX: PHARYNGEAL WALLS, PYRIFORM SINUS, AND POSTCRICOID PHARYNX 451
- Anatomy 451
- Pathology 452
- Patterns of Spread 452
- Clinical Picture 452
- Staging 452
- Treatment 453
- Results of Treatment 454
- Complications of Treatment 454
- NASOPHARYNX 454
- Anatomy 454
- Pathology 455
- Patterns of Spread 455
- Clinical Picture 455
- Staging 455
- Treatment 455
- Nasal Vestibule, Nasal Cavity, and Paranasal Sinuses 457
- Paragangliomas 462
- Major Salivary Glands 463
- Minor Salivary Glands 467

39. Rehabilitation after Treatment of Head and Neck Cancer 474*Douglas B. Chepeha, Teresa H. Lyden, and Marc Haxer*

- Introduction 474
- Pretreatment Counseling 474
- Support During Treatment and Rehabilitation of the Chemoradiation Patient 474
- Resources for Rehabilitation of Head and Neck Cancer Patients 480

SECTION 2. CANCER OF THE THORACIC CAVITY**40. Molecular Biology of Lung Cancer 482***Leora Horn, Luiz Henrique de Lima Araujo, Patrick Nana-Sinkam, Gregory A. Otterson, Terence M. Williams, and David P. Carbone*

- Introduction 482
- Susceptibility to Lung Cancer: Genetic Susceptibility and Carcinogens in Tobacco Smoke 482
- Molecular Changes in Preneoplasia 482
- Genetic and Epigenetic Alterations in Lung Cancers 484
- Protooncogenes, Growth Factor Signaling, and Growth Factor–Targeted Therapies 484
- The Technology of Genomic Analyses of Lung Cancer 486
- Epigenetics/Epigenome 487
- Tumor Suppressor Genes and Growth Suppression 487
- Cyclins and Cell Cycle Regulatory Pathways 488
- LKB1, AMPK, and mTOR Pathway 488
- Other Putative Tumor Suppressors 488
- Other Biologic Abnormalities in Lung Cancer 489
- MicroRNAs in Lung Cancer Diagnostics and Therapy 490
- MiRNA Profiling in Lung Cancer 491
- Invasion, Metastasis, and Angiogenesis 492
- Cancer Stem Cell Hypothesis 493
- Molecular Tools in the Lung Cancer Clinic 493

41. Non-Small Cell Lung Cancer 495*Frank C. Detterbeck, Roy H. Decker, Lynn Tanoue, and Rogerio C. Lilenbaum*

- Incidence and Etiology 495
- Anatomy and Pathology 498
- Prevention and Screening 502
- Diagnosis 504
- Stage Evaluation 505
- Management by Stage 508
- Special Clinical Situations 526
- Palliative Care 528
- Conclusion 530

42. Small Cell and Neuroendocrine Tumors of the Lung 536*M. Catherine Pietanza, Lee M. Krug, Abraham J. Wu, Mark G. Kris, Charles M. Rudin, and William D. Travis*

- Small Cell Lung Cancer 536
- Typical and Atypical Carcinoid Tumors 552
- Large Cell Neuroendocrine Carcinoma 555

43. Neoplasms of the Mediastinum 560*Robert B. Cameron, Patrick J. Loehrer, and Percy P. Lee*

- Thymic Neoplasms 560
- Thymoma 560
- Thymic Carcinoma 561
- Thymic Carcinoid 566
- Thymolipoma 567
- Germ Cell Tumors 567

SECTION 3. CANCERS OF THE GASTROINTESTINAL TRACT

44. Molecular Biology of the Esophagus and Stomach 570

Anil K. Rustgi

Introduction 570
Molecular Biology of Esophageal Cancer 570
Molecular Biology of Gastric Cancer 572

45. Cancer of the Esophagus 574

Mitchell C. Posner, Bruce D. Minsky, and David H. Ilson

Introduction 574
Epidemiology 574
Etiologic Factors and Predisposing Conditions 574
Applied Anatomy and Histology 577
Natural History and Patterns of Failure 579
Clinical Presentation 579
Diagnostic Studies and Pretreatment Staging 579
Pathologic Staging 581
Treatment 582
Stage-directed Treatment Recommendations 608

46. Cancer of the Stomach 613

Itzhak Avital, Alexander Stojadinovic, Peter W. T. Pisters, David P. Kelsen, and Christopher G. Willett

Introduction 613
Anatomic Considerations 613
Pathology and Tumor Biology 614
Histopathology 614
Patterns of Spread 615
Clinical Presentation and Pretreatment Evaluation 615
Pretreatment Staging 616
Staging, Classification, and Prognosis 618
Gastric Cancer Nomograms: Predicting Individual Patient Prognosis after Potentially Curative Resection 621
Treatment of Localized Disease 621
Technical Treatment-Related Issues 632
Treatment of Advanced Disease (Stage IV) 634
Surgery in Treatment of Metastatic Gastric Cancer 640
Radiation for Palliation 641

47. Genetic Testing in Stomach Cancer 643

Nicki Chun and James M. Ford

Introduction 643
Histologic Definitions and Descriptions 643
Etiology 643
Epidemiology of Gastric Cancer 644
Screening and Management of Cancer Risk in HDGC 645
Other Hereditary Cancer Susceptibility Syndromes with Increased Gastric Cancer Risk 646
Conclusions 648

48. Molecular Biology of Pancreas Cancer 651

Scott E. Kern and Ralph H. Hruban

Introduction 651
Common Molecular Changes 651

49. Cancer of the Pancreas 657

Jordan M. Winter, Jonathan R. Brody, Ross A. Abrams, Nancy L. Lewis, and Charles J. Yeo

Introduction 657
Staging 657
Epidemiology 657

Pathology and Biology 658
Exocrine Pancreatic Cancers 658
Endocrine Pancreatic Cancers 662
Stage I and II: Localized Pancreatic Ductal Adenocarcinoma 663
Stage III: Locally Advanced Disease 672
Emerging Role of Stereotactic Body Radiotherapy 675
Stage IV: Metastatic Disease 676
Future Directions and Challenges 680
Conclusion 683

50. Genetic Testing in Pancreatic Cancer 685

Jennifer E. Axilbund and Elizabeth L. Wiley

Introduction 685
Selected Genes that May Cause Pancreatic Cancer 685
Selected Syndromes that Increase the Risk of Pancreatic Cancer 687
Empiric Risk Counseling and Management 687

51. Molecular Biology of Liver Cancer 690

Jens U. Marquardt and Snorri S. Thorgeirsson

Introduction 690
Genetic Alterations in Liver Cancer 690
Epigenetic Alterations in Liver Cancer 691
Mutational Landscape of Genetic Alterations in HCC: The Next Generation 691
The Microenvironment of Liver Cancer 693
Classification and Prognostic Prediction of Hepatocellular Carcinoma 694
Conclusion and Perspective 695

52. Cancer of the Liver 696

Yuman Fong, Damian E. Dupuy, Mary Feng, and Ghassan Abou-Alfa

Introduction 696
Epidemiology 696
Etiologic Factors 696
Staging 698
Diagnosis 698
Treatment of Hepatocellular Carcinoma 699
Adjuvant and Neoadjuvant Therapy 702
Treatment of Other Primary Liver Tumors 712

53. Cancer of the Biliary Tree 715

Tushar Patel and Mitesh J. Borad

Introduction 715
Anatomy of the Biliary Tract 715
Cholangiocarcinoma 716
Gallbladder Cancer 726

54. Cancer of the Small Bowel 734

Ronald S. Chamberlain, Krishnaraj Mahendraraj, and Syed Ammer Shah

Small Bowel Cancer 734
Adenocarcinoma 736
Carcinoid Tumors 739
Small Bowel Lymphoma 740
Gastrointestinal Stromal Tumors 741
Other Mesenchymal Tumors 742
Metastatic Cancer to the Small Bowel 743

55. Gastrointestinal Stromal Tumor 745

Paolo G. Casali, Angelo Paolo Dei Tos, and Alessandro Gronchi

Introduction 745
Incidence and Etiology 745

Anatomy and Pathology 745
 Screening 747
 Diagnosis 748
 Staging 749
 Management by Stage 750
 Palliative Care 754

56. Molecular Biology of Colorectal Cancer . . . 757

Ramesh A. Shivdasani

Introduction 757
 Multistep Models of Colorectal Tumorigenesis 757
 Inherited Syndromes of Increased Cancer Risk Highlight
 Early Events and Critical Pathways in
 Colorectal Tumorigenesis 758
 Oncogene and Tumor Suppressor Gene Mutations in
 Colorectal Cancer Progression 762
 The Mutational Landscape of Colorectal Cancer 765
 An Integrated Model for Colorectal
 Cancer Initiation and Progression 766
 Summary 766

57. Cancer of the Colon 768

*Steven K. Libutti, Leonard B. Saltz, Christopher G. Willett, and
 Rebecca A. Levine*

Introduction 768
 Epidemiology 768
 Etiology: Genetic and Environmental Risk Factors 769
 Familial Colorectal Cancer 771
 Anatomy of the Colon 773
 Diagnosis of Colorectal Cancer 774
 Screening for Colorectal Cancer 775
 Staging and Prognosis of Colorectal Cancer 776
 Approaches to Surgical Resection of Colon Cancer 782
 Surgical Management of Complications from
 Primary Colon Cancer 784
 Polyps and Stage I Colon Cancer 785
 Stage II and Stage III Colon Cancer 786
 Treatment of Stage II Patients 788
 Treatment Options for Stage III Patients 790
 Follow-Up after Management of Colon Cancer
 with Curative Intent 792
 Surgical Management of Stage IV Disease 793
 Management of Unresectable Metastatic Disease 793
 Molecular Predictive Markers 808

58. Genetic Testing in Colon Cancer (Polyposis Syndromes) 813

Kory W. Jasperson

Introduction 813
 Adenomatous Polyposis 813
 Hamartomatous Polyposis 816
 Conclusions 818

59. Genetic Testing in Colon Cancer (Nonpolyposis Syndromes) 819

Leigha Senter-Jamieson

Introduction 819
 Clinical Classification: Amsterdam Criteria and
 Bethesda Guidelines 819
 Tumor Screening 819
 Genetic Testing 821
 Genetic Counseling for Lynch Syndrome 821
 Management of Lynch Syndrome 821
 Acknowledgment 821

60. Cancer of the Rectum 823

*Steven K. Libutti, Christopher G. Willett, Leonard B. Saltz, and
 Rebecca A. Levine*

Introduction 823
 Anatomy 823
 Staging 824
 Surgery 826
 Does Adjuvant Radiation Therapy Impact Survival? 832
 Preoperative Radiation Therapy 832
 Which Patients Should Receive Adjuvant Therapy? 834
 Concurrent Chemotherapy 836
 Synchronous Rectal Primary and Metastases 837
 Management of Unresectable Primary and
 Locally Advanced Disease (T4) 837
 Radiation Therapy Technique 838

61. Cancer of the Anal Region. 842

Brian G. Czito, Shahab Ahmed, Matthew Kalady, and Cathy Eng

Introduction 842
 Epidemiology and Etiology 842
 Screening and Prevention 843
 Pathology 843
 Clinical Presentation and Staging 845
 Prognostic Factors 845
 Treatment of Localized Squamous Cell Carcinoma 846
 Treatment of Other Sites and Pathologies 853

SECTION 4. CANCERS OF THE GENITOURINARY SYSTEM

62. Molecular Biology of Kidney Cancer 857

W. Marston Linehan and Laura S. Schmidt

Introduction 857
 Von Hippel-Lindau Disease 857
 Hereditary Papillary Renal Carcinoma Type 1 859
 Xp11.2 Translocation Renal Cell Cancer 859
 Birt-Hogg-Dubé Syndrome 859
 Hereditary Leiomyomatosis and Renal Cell Carcinoma 860
 Familial Renal Cancer: Succinate Dehydrogenase Gene 862
 Tuberous Sclerosis Complex 862
 Conclusion 862

63. Cancer of the Kidney 865

*Brian R. Lane, Daniel J. Canter, Brian I. Rini, and
 Robert G. Uzzo*

Introduction 865
 Epidemiology, Demographics, and Risk Factors 865
 Pathology of Renal Cell Carcinoma 865
 Differential Diagnosis and Staging 866
 Hereditary Kidney Cancer Syndromes,
 Genetics, and Molecular Biology 867
 Treatment of Localized Renal Cell Carcinoma 869
 Treatment of Locally Advanced Renal Cell Carcinoma 873
 Adjuvant Therapy for Renal Cell Carcinoma 876
 Surgical Management of Advanced Renal Cell Carcinoma 876
 Systemic Therapy for Advanced Renal Cell Carcinoma 877
 Conclusion and Future Directions 882
 Acknowledgments 882

64. Molecular Biology of Bladder Cancer 885

Margaret A. Knowles and Carolyn D. Hurst

Introduction 885
 Key Molecular Alterations in Stage Ta Urothelial Carcinoma 885
 Key Molecular Alterations in Invasive Urothelial Carcinoma 889

Information from Exome Sequencing 892
 Epigenetic Alterations 892
 Information from Expression Profiling 892
 Urothelial Tumor–Initiating Cells 893
 Molecular Pathogenesis and Tumor Clonality 893
 Multiple Tumor Subgroups Defined by Molecular Profiling 893
 Acknowledgements 894

65. Cancer of the Bladder, Ureter, and Renal Pelvis 896

Adam S. Feldman, Jason A. Efsthathiou, Richard J. Lee, Douglas M. Dahl, M. Dror Michaelson, and Anthony L. Zietman

Introduction 896
 Urothelial Cancers 896
 Cancer of the Bladder 898
 Cancers of the Renal Pelvis and Ureter 910

66. Genetic Testing in Urinary Tract Cancers . . . 917

Gayun Chan-Smutko

Introduction 917
 Genetic Susceptibility to Renal Cell Carcinoma 917
 Genetic Susceptibility to Urothelial Cancers 920
 Indications for Genetic Testing 920
 Genetic Testing and Counseling 920
 Summary 922

67. Molecular Biology of Prostate Cancer 923

Felix Y. Feng, Arul M. Chinnaiyan, and Edwin M. Posadas

Introduction 923
 Overview of the Genomic Landscape of Prostate Cancer 923
 Androgen Receptor Biology and Therapy 923
 Additional Pathways Frequently Altered
 During Disease Progression 925
 E26 Transformation Specific (ETS) Gene Fusions and the Molecular
 Subtypes of Prostate Cancer 927
 Emerging Areas in Prostate Cancer Biology and Therapy 928

68. Cancer of the Prostate 932

Howard I. Scher, Peter T. Scardino, and Michael J. Zelefsky

Introduction 932
 Incidence and Etiology 932
 Anatomy and Pathology 934
 Screening 937
 Diagnosis, Risk Assessment, and State Assignment 939
 Management by Clinical States 944
 Palliation 973
 Future Directions 974

69. Cancer of the Urethra and Penis 981

Edouard J. Trabulsi and Leonard G. Gomella

Introduction 981
 Cancer of the Male Urethra 981
 Carcinoma of the Female Urethra 982
 Cancer of the Penis 983

70. Cancer of the Testis 988

Lance C. Pagliaro and Christopher J. Logothetis

Introduction 988
 Incidence and Epidemiology 988
 Initial Presentation and Management 988
 Histology 988
 Biology 990

Immunohistochemical Markers 992
 Staging 992
 Management of Clinical Stage I Disease 995
 Management of Clinical Stage II (Low Tumor Burden) 997
 Management of Stage II with High Tumor Burden and
 Stage III Disease 998
 Management of Recurrent Disease 1000
 Treatment Sequelae 1001
 Long-Term Follow-up 1002
 Midline Tumors of Uncertain Histogenesis 1002
 Other Testicular Tumors 1002

SECTION 5. GYNECOLOGIC CANCERS

71. Molecular Biology of Gynecologic Cancers. 1005

Tanja Pejovic, Michael J. Birrer, Matthew L. Anderson, and Kunle Odunsi

Introduction 1005
 Ovarian Cancer 1005
 Endometrial Cancer 1009
 Cervix, Vaginal, and Vulvar Cancers 1010

72. Cancer of the Cervix, Vagina, and Vulva. . . 1013

Ann H. Klopp, Patricia J. Eifel, Jonathan S. Berek, and Panagiotis A. Konstantinopoulos

Carcinoma of the Vagina 1013
 Carcinoma of the Vulva 1018
 Carcinoma of the Cervix 1024

73. Cancer of the Uterine Body. 1048

Kaled M. Alektiar, Nadeem R. Abu-Rustum, and Gini F. Fleming

Endometrial Carcinoma 1048
 Uterine Sarcomas 1060

74. Genetic Testing in Uterine Cancer. 1065

Molly S. Daniels

Introduction 1065
 Lynch Syndrome (Also Known as Hereditary Nonpolyposis Colorectal
 Cancer Syndrome) 1065
 Phosphatase and Tensin Homolog Hamartoma Tumor
 Syndrome (Also Known as Cowden Syndrome,
 Bannayan-Ruvalcaba-Riley Syndrome) 1066
 Hereditary Leiomyomatosis and Renal Cell Carcinoma 1066
 Uterine Cancer and Other Hereditary Cancer Syndromes 1067
 Conclusion 1067

75. Gestational Trophoblastic Diseases 1069

Donald P. Goldstein, Ross S. Berkowitz, and Neil S. Horowitz

Introduction 1069
 Incidence 1069
 Pathology and Natural History 1069
 Indications for Treatment 1069
 Measurement of Human Chorionic Gonadotropin 1070
 Pretreatment Evaluation 1070
 Staging and Prognostic Score 1071
 Treatment 1071
 Placental Site or Epithelioid Trophoblastic Tumors 1073
 Subsequent Pregnancy after Treatment for
 Gestational Trophoblastic Neoplasia 1073
 Psychosocial Issues 1073

76. Ovarian Cancer, Fallopian Tube Carcinoma, and Peritoneal Carcinoma 1075

Stephen A. Cannistra, David M. Gershenson, and Abram Recht

Introduction 1075
Epithelial Ovarian Cancer 1075
Borderline Tumors 1092
Germ Cell Tumors of the Ovary 1093
Sex Cord–Stromal Tumors 1095
Primary Peritoneal Serous Carcinoma 1096
Fallopian Tube Cancer 1097

77. Genetic Testing in Ovarian Cancer 1100

Scott M. Weissman, Shelly M. Weiss, and Anna C. Newlin

Introduction 1100
Hereditary Breast and Ovarian Cancer Syndrome
(The BRCA1 and BRCA2 Genes) 1100
Lynch Syndrome 1102
Peutz–Jeghers Syndrome 1103
Newer Genes 1103
Conclusion 1104

SECTION 6. CANCER OF THE BREAST

78. Molecular Biology of Breast Cancer. 1107

Shaveta Vinayak, Hannah L. Gilmore, and Lyndsay N. Harris

Introduction 1107
Genetics of Breast Cancer 1107
Hereditary Breast Cancer 1107
Somatic Changes in Breast Cancer 1110
Transcriptional Profiling of Breast Cancer 1111
Epigenetics of Breast Cancer 1113
Protein/Pathway Alterations 1113
Estrogen Receptor Pathway 1113
Summary 1115

79. Malignant Tumors of the Breast 1117

Monica Morrow, Harold J. Burstein, and Jay R. Harris

Introduction 1117
Anatomy of the Breast 1117
Risk Factors for Breast Cancer 1117
Management of the High-Risk Patient 1120
Diagnosis and Biopsy 1122
Lobular Carcinoma in Situ 1122
Ductal Carcinoma in Situ 1123
Staging 1125
Pathology of Breast Cancer 1127
Local Management of Invasive Cancer 1128
Management of the Axilla 1136
Postmastectomy Radiation Therapy 1137
Prognostic and Predictive Factors in Breast Cancer 1138
Adjuvant Systemic Therapy 1140
Integration of Multimodality Primary Therapy 1144
Follow-Up for Breast Cancer Survivors 1144
Special Therapeutic Problems 1145
Management of Local-Regional Recurrence 1148
Metastatic Disease 1148

80. Genetic Testing in Breast Cancer 1157

Kristen M. Shannon and Anu Chittenden

Introduction 1157
Identification of High-Risk Individuals 1157
Genetic Testing 1157
BRCA1 and BRCA2 1157

TP53 1159

Cowden Syndrome (Phosphate and Tensin Homolog) 1160
Other Genetic Mutations and Breast Cancer 1162
Moderate- and Low-Penetrance Breast Cancer Genes 1162
Conclusion 1163

SECTION 7. CANCER OF THE ENDOCRINE SYSTEM

81. Molecular Biology of Endocrine Tumors . . 1166

Samuel A. Wells, Jr.

Introduction 1166
The Multiple Endocrine Neoplasia Syndromes 1166
Application of Molecular Genetics to Clinical Medicine 1171
Thyroid Carcinomas 1171
Future Directions 1173

82. Thyroid Tumors. 1175

Caroline J. Davidge-Pitts and Geoffrey B. Thompson

Anatomy and Physiology 1175
Thyroid Nodules 1175
Thyroid Tumor Classification and Staging Systems 1177
Differentiated Thyroid Cancer 1177
Treatment of Differentiated Thyroid Cancer 1180
Anaplastic Thyroid Carcinoma 1183
Medullary Thyroid Cancer 1184
Thyroid Lymphoma 1186
Children with Thyroid Carcinoma 1187

83. Parathyroid Tumors 1189

Marcio L. Griebeler and Geoffrey B. Thompson

Incidence and Etiology 1189
Anatomy and Pathology 1189
Clinical Manifestations and Screening 1190
Diagnosis 1190
Staging 1191
Management of Parathyroid Cancer 1191
Follow-Up and Natural History 1192
Prognosis 1192

84. Adrenal Tumors 1195

Roy Lirov, Tobias Else, Antonio M. Lerario, and Gary D. Hammer

Introduction 1195
Overview and Pathophysiology of the Adrenal Gland 1195
Molecular Genetics of Adrenal Neoplasms 1196
Incidence and Epidemiology 1196
Screening in Special Populations 1197
Diagnosis of Adrenal Neoplasia 1197
Grading and Staging of Malignancy 1199
Important Considerations in Perioperative Management of Adrenal Tumors 1199
Management of Benign-Appearing Adrenocortical Tumors and Pheochromocytoma 1200
Surveillance after Resection of Pheochromocytoma 1200
Management of Recurrent or Metastatic Malignant Pheochromocytoma 1200
Management of Local and Locoregionally Advanced Adrenocortical Carcinoma 1201
Surveillance and Adjuvant Therapy for Adrenocortical Carcinoma 1201
Management of Locoregional Recurrence of Adrenocortical Carcinoma 1202
Management of Isolated Metastases of Adrenocortical Carcinoma 1202

Management of Metastatic or Unresectable

Adrenocortical Carcinoma 1202

Emerging Diagnostic Techniques and Treatment

Strategies for Adrenal Tumors 1203

Special Considerations in Pregnancy 1203

Adrenal Neoplasia in Childhood 1203

Acknowledgments 1203

85. Pancreatic Neuroendocrine Tumors 1205*James C. Yao and Douglas B. Evans*

Introduction 1205

Epidemiology 1205

Classification, Histopathology, Molecular Genetics 1205

Diagnosis and Management of Pancreatic

Neuroendocrine Tumors 1208

Additional Clinical Considerations 1215

Surgery Pitfalls 1216

86. Carcinoid Tumors and the Carcinoid Syndrome 1218*Jeffrey A. Norton and Pamela L. Kunz*

Incidence and Etiology 1218

Anatomy and Pathology 1218

General Principles of Neuroendocrine Tumor Diagnosis, Staging, and Management 1218

Diagnosis, Staging, and Management by Primary Tumor Site 1220

Diagnosis and Management of Carcinoid Syndrome 1222

Antitumor Management 1223

Management of Liver Metastases 1224

Conclusions 1225

87. Multiple Endocrine Neoplasias 1227*Jeffrey A. Norton and Pamela L. Kunz*

Introduction 1227

Multiple Endocrine Neoplasia Type 1 1227

Multiple Endocrine Neoplasia Type 2, Type 3, and

Familial Medullary Thyroid Cancer 1230

Multiple Endocrine Neoplasia Type 4 1232

88. Genetic Testing in the Endocrine System . . . 1234*Robert Pilarski and Rebecca Nagy*

Introduction 1234

Multiple Endocrine Neoplasia Type 1 1234

Multiple Endocrine Neoplasia Type 2 1235

Phosphatase and Tensin Homolog on Chromosome 10 1236

SDHX/TMEM127/MAX 1237

Von Hippel-Lindau and Pheochromocytoma 1238

SECTION 8. SARCOMAS OF SOFT TISSUE AND BONE**89. Molecular Biology of Sarcomas 1241***Samuel Singer, Torsten O. Nielsen, and Cristina R. Antonescu*

Introduction 1241

SOFT TISSUE SARCOMAS 1241

Translocation-Associated Soft Tissue Sarcomas 1241

Soft Tissue Sarcomas of Simple Karyotype

Associated with Mutations 1247

Complex Soft Tissue Sarcoma Types 1247

BONE AND CARTILAGINOUS TUMORS 1249

Cartilaginous Tumors 1249

Osteosarcoma 1250

Future Directions: Next-Generation Sequencing and

Functional Screens 1251

90. Soft Tissue Sarcoma 1253*Samuel Singer, William D. Tap, Aimee M. Crago, and Brian O'Sullivan*

Introduction 1253

Incidence and Etiology 1253

Anatomic and Age Distribution and Pathology 1254

Diagnosis and Staging 1266

Management by Presentation Status, Extent of Disease, and Anatomic Location 1270

Palliative Care 1289

Future Directions 1290

91. Sarcomas of Bone 1292*Richard J. O'Donnell, Steven G. DuBois, and Daphne A. Haas-Kogan*

Introduction 1292

Incidence and Etiology 1292

Anatomy and Pathology 1293

Screening 1294

Diagnosis 1294

Staging 1297

Management by Diagnosis and Stage 1297

Continuing Care: Surveillance and Palliation 1310

SECTION 9. CANCERS OF THE SKIN**92. Cancer of the Skin 1314***Sean R. Christensen and David J. Leffell*

Introduction 1314

NONMELANOMA SKIN CANCER 1314

Diagnosis 1314

General Approach to Management of Skin Cancer 1314

Topical Therapy for Skin Cancer 1317

Radiation Therapy for Skin Cancer 1318

ACTINIC KERATOSES 1318

Pathogenesis of Actinic Keratosis 1318

Clinical Features of Actinic Keratosis 1318

Treatment of Actinic Keratosis 1319

BASAL CELL CARCINOMA 1320

Clinical Behavior of Basal Cell Carcinoma 1321

Basal Cell Carcinoma Subtypes 1321

Histology 1322

Treatment 1323

SQUAMOUS CELL CARCINOMA 1323

Pathogenesis of Squamous Cell Carcinoma 1324

Clinical Features of Squamous Cell Carcinoma and its Variants 1324

Histology 1325

Clinical Behavior of Squamous Cell Carcinoma 1325

Treatment 1326

Follow-Up 1327

Immunosuppression and Nonmelanoma Skin Cancer 1327

ANGIOSARCOMA 1328

Pathogenesis 1328

Clinical Presentation and Prognosis 1328

Histology 1328

Treatment 1328

DERMATOFIBROSARCOMA PROTUBERANS 1329

Pathogenesis 1329

Histology 1329

Treatment 1329

Recurrence and Metastatic Potential 1329

MERKEL CELL CARCINOMA 1330

Pathogenesis 1330

Clinical Presentation 1330

Histology 1330

Treatment 1331

Staging	1331
Recurrence and Metastatic Risk	1331
Prognosis	1332
MICROCYSTIC ADNEXAL CARCINOMA	1332
Clinical and Histologic Features	1332
Treatment and Prognosis	1332
SEBACEOUS CARCINOMA	1332
Clinical and Histologic Features	1333
Treatment and Prognosis	1333
EXTRAMAMMARY PAGET DISEASE	1333
Clinical and Histologic Features	1333
Treatment and Prognosis	1333
ATYPICAL FIBROXANTHOMA AND MALIGNANT FIBROUS HISTIOCYTOMA	1333
ATYPICAL FIBROXANTHOMA	1334
Clinical and Histologic Features	1334
Treatment and Prognosis	1334
CARCINOMA METASTATIC TO SKIN	1334
93. Molecular Biology of Cutaneous Melanoma	1337
<i>Michael A. Davies and Levi A. Garraway</i>	

Introduction	1337
The RAS-RAF-MAP Kinase Pathway	1337
The MEK Pathway and Therapeutic Resistance	1341
Melanin Synthesis Pathway	1343
Molecular Genetics of Melanoma: Looking Ahead	1344
94. Cutaneous Melanoma	1346
<i>Antoni Ribas, Craig L. Slinghuff, Jr., and Steven A. Rosenberg</i>	

Introduction	1346
Molecular Biology of Melanoma	1346
Epidemiology	1349
Changes in Incidence	1350
Gender and Age Distribution	1350
Melanoma in Children, Infants, and Neonates	1350
Anatomic Distribution	1350
Etiology and Risk Factors	1351
Prevention and Screening	1352
Diagnosis of Primary Melanoma	1353
General Considerations in Clinical Management of a Newly Diagnosed Cutaneous Melanoma (Stage I-II)	1358
Clinical Trials to Define Margins of Excision for Primary Cutaneous Melanomas	1359
Surgical Staging of Regional Nodes	1360
Management	1363
Special Considerations in Management of Primary Melanomas	1365
The Role of Radiation Therapy in the Management of Primary Melanoma Lesions	1366
Clinical Follow-Up for Intermediate-Thickness and Thick Melanomas (Stage IB–IIC)	1366
Regionally Metastatic Melanoma (Stage III): Lymph Node Metastasis, Satellite Lesions, and In-Transit Metastases	1367
Management of Regional Metastases in Patients with Visceral or Other Distant Disease	1370
Adjuvant Systemic Therapy (Stages IIB, IIC, and III)	1371
Management of Distant Metastases of Melanoma (Stage IV)	1376
Experimental Immunologic Therapies for Metastatic Melanoma	1386
Radiation Therapy for Metastatic Melanoma (Stage IV)	1388

95. Genetic Testing in Skin Cancer	1395
<i>Michele Gabree and Meredith L. Seidel</i>	

Introduction	1395
Genetic Counseling	1395

Hereditary Skin Cancer and the Neurofibromatosis	1395
Conclusion	1401

SECTION 10. NEOPLASMS OF THE CENTRAL NERVOUS SYSTEM

96. Molecular Biology of Central Nervous System Tumors	1403
---	-------------

Victoria Clark, and Jennifer Moliterno Günel, and Murat Günel

Gliomas	1403
Meningiomas	1405
Medulloblastomas	1407
Ependymal Tumors	1409
Summary	1410

97. Neoplasms of the Central Nervous System	1412
--	-------------

Susan M. Chang, Minesh P. Mehta, Michael A. Vogelbaum, Michael D. Taylor, and Manmeet S. Ahluwalia

Epidemiology of Brain Tumors	1412
Classification	1413
Anatomic Location and Clinical Considerations	1415
Neurodiagnostic Tests	1416
Surgery	1417
Radiation Therapy	1418
Chemotherapy and Targeted Agents	1420
Specific Central Nervous System Neoplasms	1421
Gliomatosis Cerebri	1429
Optic, Chiasmal, and Hypothalamic Gliomas	1429
Brainstem Gliomas	1431
Cerebellar Astrocytomas	1432
Gangliogliomas	1432
Ependymoma	1433
Meningiomas	1434
Primitive Neuroectodermal or Embryonal Central Nervous System Neoplasms	1437
Pineal Region Tumors and Germ Cell Tumors	1439
Pituitary Adenomas	1441
Craniopharyngiomas	1443
Vestibular Schwannomas	1444
Glomus Jugulare Tumors	1445
Hemangioblastomas	1446
Chordomas and Chondrosarcomas	1447
Choroid Plexus Tumors	1449
Spinal Axis Tumors	1449

SECTION 11. CANCERS OF CHILDHOOD

98. Molecular Biology of Childhood Cancers	1456
---	-------------

Lee J. Helman and David Malkin

Introduction	1456
Tumor Suppressor Genes	1456
Retinoblastoma: The Paradigm	1458
SDH Deficient Gist	1458
Neurofibromatosis	1459
Neuroblastoma	1459
Ewing Sarcoma Family of Tumors	1460
Rhabdomyosarcoma	1460
Hereditary Syndromes Associated with Tumors of Childhood Li-Fraumeni Syndrome	1461
Malignant Rhabdoid Tumors	1462
DICER1 Syndrome	1462
Predictive Testing for Germ-Line Mutations and Childhood Cancers	1462
Molecular Therapeutics	1463

99. Solid Tumors of Childhood 1465

Alberto S. Pappo, Fariba Navid, Rachel C. Brenman, Matthew J. Krasin, Andrew M. Davidoff, and Wayne L. Furman

Introduction 1465
Multidisciplinary Care is Essential for Children and Adolescents with Solid Tumors 1465
Neuroblastoma 1465
Wilms Tumor 1474
Retinoblastoma 1477
Pediatric Bone Sarcomas: Osteosarcoma and Ewing Sarcoma 1481
Rhabdomyosarcoma 1488
Hepatoblastoma 1492
Germ Cell Tumors 1495

100. Leukemias and Lymphomas of Childhood 1500

Karen R. Rabin, Judith F. Margolin, Kala Y. Kamdar, and David G. Poplack

Introduction 1500
Leukemias 1500
Lymphomas 1506
Supportive Care 1509
Long-Term, Palliative, and Hospice Care in Pediatric Oncology 1509

SECTION 12. LYMPHOMAS IN ADULTS

101. Molecular Biology of Lymphomas 1511

Laura Pasqualucci and Riccardo Dalla-Favera

Introduction 1511
The Cell of Origin of Lymphoma 1511
General Mechanisms of Genetic Lesions In Lymphoma 1513
Molecular Pathogenesis of B-NHL 1515
Molecular Pathogenesis of T-Cell Non-Hodgkin Lymphoma 1522
Molecular Pathogenesis of Hodgkin Lymphoma 1524

102. Hodgkin's Lymphoma 1526

Anas Younes, Antonino Carbone, Peter Johnson, Bouthaina Dabaja, Stephen Ansell, and John Kuruvilla

Introduction 1526
Biology of Hodgkin's Lymphoma 1526
Pathology of Hodgkin's Lymphoma 1527
Differential Diagnosis 1531
Early-Stage Hodgkin's Lymphoma 1533
Advanced-Stage Hodgkin's Lymphoma 1535
Special Circumstances 1540
Treatment 1541

103. Non-Hodgkin's Lymphoma 1552

Arnold S. Freedman, Caron A. Jacobson, Peter Mauch, and Jon C. Aster

Introduction 1552
Epidemiology and Etiology 1552
Biologic Background for Classification of Lymphoid Neoplasms 1553
Lymphoma Classification: The Principles of the World Health Organization (WHO) Classification of Lymphoid Neoplasms 1556
Principles of Management of Non-Hodgkin's Lymphoma 1558
Specific Disease Entities 1560
Mature T-Cell and Natural Killer Cell Neoplasms 1574

104. Cutaneous Lymphomas 1584

Francine M. Foss, Juliet F. Gibson, Richard L. Edelson, and Lynn D. Wilson

Introduction 1584
Mycosis Fungoides and the Sézary Syndrome 1584
Diagnosis and Staging 1585
Clinical Evaluation of Patients with Cutaneous Lymphoma 1588
Principles of Therapy of Mycosis Fungoides and the Sézary Syndrome 1588
Systemic Therapy for Mycosis Fungoides and the Sézary Syndrome 1592
Other Cutaneous Lymphomas 1594

105. Primary Central Nervous System Lymphoma 1597

Tracy T. Batchelor

Epidemiology 1597
Pathology 1597
Diagnosis and Prognostic Factors 1597
Staging 1597
Treatment 1598

SECTION 13. LEUKEMIAS AND PLASMA CELL TUMORS

106. Molecular Biology of Acute Leukemias 1602

Glen D. Raffel and Jan Cerny

Introduction 1602
Leukemic Stem Cell 1602
Elucidation of Genetic Events in Acute Leukemia 1602
Mutations that Target Core-Binding Factor 1605
Chromosomal Translocations that Target the Retinoic Acid Receptor Alpha Gene 1606
Mutations that Target Hox Family Members 1607
Chromosomal Translocations that Target the *MLL* Gene 1607
Mutation of *C/Ebpa* 1608
Mutation of *GATA-1* 1608
t(1;22) Translocation Associated with Infant AMKL 1608
Mutations of Epigenetic Modifiers 1608
Chromosomal Translocations that Result in Overexpression of *c-MYC* 1609
Chromosomal Translocations Involving the T-Cell Receptor 1609
Point Mutations in Acute Leukemia 1609
Mutations in Tumor Suppressor Genes 1610
Activating Mutations of Notch 1611
Mutations Altering Localization of *NPM1* 1611
Mutation of Lymphoid Development Genes in Acute Lymphoid Leukemia 1611
Mutational Complementations Groups in Acute Leukemias 1612
Conclusion 1613

107. Management of Acute Leukemias 1615

Partow Kebriaei, Marcos de Lima, Elihu H. Estey, and Richard Champlin

Introduction 1615
Acute Myelogenous Leukemia 1616
Acute Lymphoblastic Leukemia 1628

108. Molecular Biology of Chronic Leukemias . . . 1637

James S. Blachly, Christopher A. Eide, John C. Byrd, and Anupriya Agarwal

Introduction 1637
Chronic Myeloid Leukemia 1637
Chronic Lymphocytic Leukemia 1640
Acknowledgments 1642

109. Chronic Myelogenous Leukemia 1644*Brian J. Druker and David Marin*

Introduction 1644
 Epidemiology 1644
 Pathogenesis 1644
 Diagnosis 1645
 Prognostic Factors 1646
 Therapy 1646
 Advanced Phase Disease 1652
 Future Directions 1652

110. Chronic Lymphocytic Leukemias 1654*William G. Wierda and Susan M. O'Brien*

Introduction 1654
 Molecular Biology 1654
 Immune Abnormalities 1656
 Diagnosis 1656
 Treatment and Response Criteria 1658
 New and Novel Treatments for Chronic
 Lymphocytic Leukemia 1666
 Second Malignancies and Transformation 1667
 Prolymphocytic Leukemia 1667
 Large Granular Lymphocyte Leukemia 1667
 Hairy Cell Leukemia 1668

111. Myelodysplastic Syndromes 1671*Rami S. Komrokji, Eric Padron, and Alan F. List*

Introduction 1671
 Historical Perspective 1671
 Epidemiology 1671
 Etiology 1671
 Pathology 1672
 Pathogenesis 1672
 Clinical Presentation 1675
 Risk Assessment and Prognosis 1676
 Management of Myelodysplastic Syndromes 1676

112. Plasma Cell Neoplasms 1682*Nikhil C. Munshi and Kenneth C. Anderson*

Introduction 1682
 History 1682
 Epidemiology 1683
 Etiology 1683
 Pathogenesis 1684
 Drug Resistance 1690
 Clinical Manifestations 1691
 Treatment 1700

SECTION 14. OTHER CANCERS**113. Cancer of Unknown Primary Site 1720***F. Anthony Greco and John D. Hainsworth*

Introduction 1720
 Pathologic Evaluation 1720
 Studies of Molecular Gene Expression Tumor Profiling Assays in Cancer
 of Unknown Primary Diagnosis 1724
 Clinical Features and Evaluation 1727
 Treatment 1728
 Special Issues in Carcinoma of Unknown Primary Site 1734
 Unknown Primary Cancer in Children 1735
 New Treatment Paradigm 1735

114. Benign and Malignant Mesothelioma 1738*Harvey I. Pass, Michele Carbone, Lee M. Krug, and
Kenneth E. Rosenzweig*

Introduction 1738
 Mechanism of Asbestos Carcinogenesis 1738
 Overview of Molecular Mechanisms in Mesothelioma 1739
 Alterations of Oncogenes in Mesothelioma 1740
 Pathology of Mesothelioma 1742
 Epidemiology and Clinical Presentation 1743
 Diagnostic Approach for Presumed Mesothelioma 1744
 Natural History 1747
 Treatment 1748
 Surgery for Pleural Mesothelioma 1750
 Controversy Regarding Performance of Extrapleural
 Pneumonectomy 1751
 Evolution of Lung Sparing Approaches for Macroscopic Complete
 Resection 1753
 Chemotherapy 1754
 Novel Therapeutic Approaches 1755
 Radiotherapy For Mesothelioma 1756

**115. Peritoneal Metastases and
Peritoneal Mesothelioma 1761***Marcello Deraco, Dominique M. Elias, Olivier Glehen,
C. William Helm, Paul H. Sugarbaker, and Vic J. Vervaal*

Introduction 1761
 Natural History Studies Document the Importance of
 Local-Regional Progression 1761
 Patient Selection Using Quantitative Prognostic Indicators 1761
 Appendiceal Malignancy 1763
 Colorectal Peritoneal Metastases: Curative Treatment and
 Prevention 1764
 Diffuse Malignant Peritoneal Mesothelioma 1765
 Gastric Cancer 1766
 Peritoneal Metastases in Ovarian Cancer 1767
 Sarcomatosis 1768

116. Intraocular Melanoma 1770*Paul T. Finger*

Introduction 1770
 Incidence and Etiology 1770
 Anatomy and Pathology 1770
 Ophthalmic Diagnosis 1771
 Universal Staging and Uveal Melanoma 1773
 Management of the Primary Uveal Melanoma 1773
 Treatment for Special Cases 1775
 Quality of Life 1776
 Diagnosis of Uveal Melanoma Metastasis 1776
 Biomarkers: Prognostic and Predictive Factors 1778
 Summary 1778

**SECTION 15. IMMUNOSUPPRESSION
RELATED MALIGNANCIES****117. HIV-Associated Malignancies 1780***Robert Yarchoan, Thomas S. Uldrick, Mark N. Polizzotto, and
Richard F. Little*

Introduction 1780
 Cancer and HIV: Incidence and Etiology 1780
 Kaposi Sarcoma 1782
 Lymphoid Tumors in Patients with HIV 1785
 Human Papillomavirus–Associated Cancer in HIV Infection 1791
 Future Directions 1792

118. Transplantation-Related Malignancies . . . 1794*Smita Bhatia and Ravi Bhatia*

Introduction 1794

Myelodysplasia and Acute Myeloid Leukemia 1794

Lymphomas 1799

Solid Tumors 1800

SECTION 16. ONCOLOGIC EMERGENCIES**119. Superior Vena Cava Syndrome 1804***Andreas Rimmer and Joachim Yahalom*

Introduction 1804

Anatomy and Pathophysiology 1804

Clinical Presentation and Etiology 1804

Diagnostic Workup 1806

Disease-Specific Management and Outcomes 1806

Small-Cell Lung Cancer 1806

Non-Small-Cell Lung Cancer 1806

Non-Hodgkin Lymphoma 1806

Nonmalignant Causes 1807

Catheter-Induced Obstruction 1807

Treatment 1807

Areas of Uncertainty 1808

Recommendations 1808

120. Increased Intracranial Pressure 1810*Kevin P. Becker and Joachim M. Baehring*

Introduction 1810

Pathophysiologic Considerations 1810

Epidemiology and Pathogenesis 1811

Clinical Presentation 1812

Diagnosis 1813

Treatment 1814

121. Spinal Cord Compression 1816*Kevin P. Becker and Joachim M. Baehring*

Introduction 1816

Epidemiology 1816

Pathophysiology 1816

Clinical Presentation 1818

Differential Diagnosis 1818

Diagnosis 1818

Treatment 1819

Prognosis 1820

122. Metabolic Emergencies 1822*Antonio Tito Fojo*

Introduction 1822

Tumor Lysis Syndrome and Hyperuricemia 1822

Cancer and Hyponatremia 1826

Lactic Acidosis and Cancer 1827

Hypercalcemia and Cancer 1829

Cancer-Related Hemolytic Uremic Syndrome 1830

SECTION 17. TREATMENT OF METASTATIC CANCER**123. Metastatic Cancer to the Brain 1832***John H. Suh, Samuel T. Chao, David M. Peereboom, and Gene H. Barnett*

Introduction 1832

Leptomeningeal Metastases 1842

124. Metastatic Cancer to the Lung 1845*Jessica S. Donington and Christopher W. Towe*

Introduction 1845

Presentation and Diagnosis of Pulmonary Metastases 1845

Surgical Metastasectomy 1846

Ablative Therapies 1849

Treatment Concerns and Outcomes for Individual Histologies 1850

Conclusion 1853

125. Metastatic Cancer to the Liver 1855*Clifford S. Cho, Samuel J. Lubner, and Brian D. Kavanagh*

Introduction 1855

Hepatic Colorectal Adenocarcinoma Metastases 1858

Hepatic Neuroendocrine Carcinoma Metastases 1864

Noncolorectal Nonneuroendocrine Hepatic Metastases 1865

126. Metastatic Cancer to the Bone 1867*Edward Chow, Joel A. Finkelstein, Arjun Sahgal, and Robert E. Coleman*

Introduction 1867

Presentation 1867

Pathophysiology 1867

Diagnostic Evaluation 1867

Therapeutic Modalities 1867

Denosumab 1869

New Targeted Therapies in the Treatment of Metastatic Bone Disease 1869

External Beam Radiation Therapy 1869

Systemic Radionuclides 1871

Radiotherapy for Complications of Bone Metastases: Localized External Beam Radiotherapy for Pathologic Fractures 1872

Mechanical Stability and Fracture Risk 1874

127. Malignant Pleural and Pericardial Effusions 1880*Dao M. Nguyen and Eddie W. Manning, III*

Malignant Pleural Effusion 1880

Malignant Pericardial Effusion 1883

128. Malignant Ascites 1887*Ajay V. Maker*

Incidence and Etiology 1887

Anatomy and Pathology 1887

Diagnosis 1888

Management 1889

129. Paraneoplastic Syndromes 1893*Ramaswamy Govindan, Thomas E. Stinchcombe, and Daniel Morgensztern*

Introduction 1893

Paraneoplastic Neurologic Syndromes 1893

Paraneoplastic Endocrinology Syndromes 1897

Paraneoplastic Hematologic Syndromes 1901

Paraneoplastic Dermatologic Manifestations 1902

Paraneoplastic Rheumatologic Manifestations 1904

SECTION 18. STEM CELL TRANSPLANTATION**130. Autologous Stem Cell Transplantation . . . 1907***Hillard M. Lazarus, Mehdi Hamadani, and Parameswaran N. Hari*

Introduction 1907

Autologous Hematopoietic Progenitor Cell Collection 1907

Autologous Hematopoietic Cell Transplantation Toxicities and Supportive Care	1907
Indications For Autologous Hematopoietic Cell Transplantation	1908
Autologous Hematopoietic Cell Transplantation for Plasma Cell Myeloma	1908
Autologous Hematopoietic Cell Transplantation for Lymphoid Malignancies	1911
Autologous Hematopoietic Cell Transplantation for Rarer Plasma Cell Dyscrasias	1914
Autologous Hematopoietic Cell Transplantation for Acute Myeloid Leukemia And Acute Lymphoblastic Leukemia	1914
Autologous Hematopoietic Cell Transplantation for Germ Cell Tumors	1915
Late Complications After Autologous Hematopoietic Cell Transplantation	1915

131. Allogeneic Stem Cell Transplantation. . . . 1917

Stanley R. Riddell and Edus H. Warren

Introduction	1917
Conditioning Regimens	1917
Stem Cell Sources	1918
Immunobiology of Allogeneic Hematopoietic Cell Transplantation	1920
Complications of Allogeneic Hematopoietic Cell Transplantation and their Management	1921
Graft Failure	1925
Outcome of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies and Solid Tumors	1926
Management of Posttransplant Relapse	1929
Future Directions	1929

SECTION 19. MANAGEMENT OF ADVERSE EFFECTS OF TREATMENT

132. Infections in the Cancer Patient 1931

Tara N. Palmore, Mark Parta, Jennifer Cuellar-Rodriguez, and Juan C. Gea-Banacloche

RISK FACTORS FOR INFECTIONS IN PATIENTS WITH CANCER AND ANTIMICROBIAL PROPHYLAXIS	1931
Risk Factors for Infection	1931
Prevention of Infections	1937
DIAGNOSIS AND MANAGEMENT OF INFECTIOUS DISEASES SYNDROMES	1939
Fever and Neutropenia	1939
Multidrug Resistant Organisms of Interest in Oncology	1954

133. Neutropenia and Thrombocytopenia 1960

Lodovico Balducci, Bijal Shah, and Kenneth Zuckerman

Introduction	1960
--------------	------

134. Cancer Associated Thrombosis. 1969

Agnes Y. Y. Lee and Alok A. Khorana

Introduction	1969
Mechanisms of Cancer-Associated Thrombosis	1969
Epidemiology of Cancer-Associated Thrombosis	1970
Prevention of Cancer-Associated Thrombosis	1972
Treatment of Cancer-Associated Thrombosis	1973

135. Nausea And Vomiting 1976

Elizabeth M. Blanchard and Paul J. Hesketh

Introduction	1976
Nausea and Vomiting Syndromes	1976
Pathophysiology of Treatment-Induced Nausea and Vomiting	1976
Defining the Risk of Nausea and Vomiting	1977

Antiemetic Agents	1978
Antiemetic Treatment by Clinical Setting	1980
Special Chemotherapy-Induced Nausea and Vomiting Problems	1981
Radiotherapy-Induced Nausea and Vomiting	1981

136. Diarrhea and Constipation 1984

Nathan I. Cherny and Batsheva Werman

Introduction	1984
Diarrhea	1984
Constipation	1988
Conclusion	1990

137. Oral Complications. 1992

Eliezer Soto, Jane M. Fall-Dickson, and Ann M. Berger

Introduction	1992
Oral Mucositis	1992
Chemotherapy-Induced Mucositis	1992
Radiation-Induced Mucositis	1992
Radiation Therapy-Related Complications	1992
Pathogenesis of Chemotherapy- and Radiation-Induced Oral Mucositis	1993
Chronic Graft-Versus-Host Disease Oral Manifestations	1993
Sequelae of Oral Complications	1994
Strategies for Prevention and Treatment of Oral Complications	1994
Treatment Strategies	1995
Radioprotectors	1995
Biologic Response Modifiers	1997
Treatment for Oral Chronic Graft-Versus-Host Disease	2000
Symptom Management	2000

138. Pulmonary Toxicity. 2004

Diane E. Stover, Caroline M. Gulati, Alexander I. Geyer, and Robert J. Kaner

Introduction	2004
Radiation-Induced Pulmonary Toxicity	2004
Chemotherapy-Induced Pulmonary Toxicity	2006

139. Cardiac Toxicity. 2014

Joachim Yahalom and Matthew A. Lunning

Introduction	2014
Chemotherapeutics	2014
Radiotherapy-Associated Cardiac Sequelae	2017
Conclusion	2020

140. Hair Loss. 2022

Joyson J. Karakunnel, Ibrahim M. Qazi, and Ann M. Berger

Introduction	2022
Anatomy and Physiology	2022
Classification	2022
Diagnosis	2022
Treatment	2023

141. Gonadal Dysfunction 2026

George Patounakis, Alan H. DeCherney, and Alicia Y. Armstrong

Introduction	2026
Effects of Cytotoxic Agents on Adult Men	2026
Effects of Cytotoxic Agents on Adult Women	2030
Effects of Cytotoxic Agents on Children	2032
Gonadal Dysfunction after Cranial Irradiation	2032
Preservation of Fertility, Hormone Levels, and Sexual Function	2033

Pharmacologic Attempts at Preserving Fertility in Men	2036
Pharmacologic Attempts at Preserving Fertility in Women	2036
Fertility Preservation in Women with Cervical Cancer	2037
Evaluation of Fertility after Treatment	2037
Hormone Replacement Therapy	2037
Prevention and Management of Erectile and Ejaculatory Dysfunction	2038
Genetic Concerns	2038
Acknowledgments	2039

142. Fatigue 2041

Sandra A. Mitchell and Ann M. Berger

Introduction	2041
Definition and Etiology of Cancer-Related Fatigue	2041
Current Theories of Cancer-Related Fatigue	2041
Evaluation of the Patient with Cancer-Related Fatigue	2042
Interventions for Fatigue	2043
Pharmacologic Measures	2044
Treatment of Anemia with Erythropoiesis-Stimulating Agents	2044
Exercise	2044
Management of Concurrent Symptoms	2044
Psychoeducational Interventions	2045
Interventions to Improve Sleep Quality	2045
Structured Rehabilitation	2045
Integrative Therapies	2045
Summary	2045

143. Second Cancers 2047

Lois B. Travis, Smrita Bhatia, James M. Allan, Kevin C. Oeffinger, and Andrea Ng

Introduction	2047
Carcinogenicity of Individual Treatment Modalities	2047
Genetic Susceptibility to Second Primary Cancers	2051
Risk of Second Malignancy in Patients with Selected Primary Cancers	2054
Pediatric Malignancies	2059
Comments	2065

144. Neurocognitive Effects 2068

Paul D. Brown, Sanne B. Schagen, and Jeffrey S. Wefel

Introduction	2068
Assessment of Cognitive Function	2068
Impact of Tumor	2068
Impact of Treatment	2069
Treatment of Cognitive Dysfunction	2072
Conclusion	2073

145. Cancer Survivorship 2074

Wendy Landier, Craig C. Earle, Smrita Bhatia, Melissa M. Hudson, Kevin C. Oeffinger, Patricia A. Ganz, and Louis S. Constine

Introduction	2074
Definition of Survivorship and Scope of the Problem	2074
Goals of Survivorship Health Care	2075
Care Plans	2078
Delivery of Follow-Up Care and Best Practice Models	2079
Educational Considerations	2079
Enhancing Research	2079
Survivorship Advocacy	2080
Conclusion	2080

PART VI

Palliative and Alternative Care

SECTION 1. SUPPORTIVE CARE AND QUALITY OF LIFE

146. Management of Cancer Pain 2084

Thomas W. LeBlanc and Amy P. Abernethy

Introduction	2084
Epidemiology	2084
Definition of Pain	2085
Common Pain Syndromes	2087
Management of Cancer Pain	2089
Psychological Approaches	2099
Anesthetic and Neurosurgical Approaches	2099
Neuropharmacologic Approaches	2101
Neuroablative and Neurostimulatory Procedures for the Relief of Pain	2102
Trigger Point Injection and Acupuncture	2102
Physiatric Approaches	2102
Algorithm for Cancer Pain Management	2102
Future Directions	2102

147. Nutritional Support 2105

Laleh G. Melstrom, Vadim P. Koshenkov, and David A. August

Background	2105
Causes of Malnutrition in Cancer Patients	2105
Cancer Cachexia Syndrome	2105
Nutrition Screening and Assessment	2107
Pharmacotherapy of Cancer-Associated Weight Loss and Malnutrition	2107
Nutrition Support of Cancer Patients	2108
Effect of Nutrition Support on Tumor Growth	2110
Glycemic Control in Patients with Cancer	2110
Palliative Nutrition Support in Patients Not Receiving Anticancer Treatment	2110

148. Sexual Problems 2112

Veronica Sanchez Varela, Eric S. Zhou, and Sharon L. Bober

Introduction	2112
Cancer in Men	2112
Cancers that Affect Men and Women	2114
Cancer in Women	2115
Cancer in Children and Young Adults	2118
Relevant Sociocultural Considerations	2118
Disruption of Intimacy and Relational Considerations	2119

149. Psychological Issues 2122

David Spiegel and Michelle B. Riba

Introduction	2122
Common Psychiatric Conditions	2122
Screening for Psychological Problems	2122
Coping	2123
Treatment Interventions	2123
Outcome	2125
Implications for Cancer Progression and Mortality	2126
Psychotropic Medication	2126

150. Communicating News to the Cancer Patient 2130

Eric J. Cassell

Introduction 2130
Preventing Illness 2130
Communication 2130
Explanations 2131
Uncomfortable Questions 2131
Information 2132
Meaning 2132
Cafeteria Explanations 2132

151. Specialized Care of the Terminally Ill 2134

Robert S. Krouse and F. Amos Bailey

Introduction 2134
Interdisciplinary Care for Patients with Advanced Cancer 2134
Early Palliative Care 2134
Communication 2134
Specific Problems in the Setting of Advanced Cancer 2134
Dyspnea 2135
Malignant Bowel Obstruction 2135
Malignant Biliary Obstruction 2136
Gastric Outlet Obstruction 2136
Malignant Ascites 2136
Wounds 2137
Bleeding 2138
Impending Death 2138

152. Rehabilitation of the Cancer Patient. 2141

Michael D. Stubblefield

Introduction 2141
Complications of Cancer and its Treatment 2141
Neuromuscular Complications of Cancer and Cancer Treatment 2144
Musculoskeletal Complications of Cancer and Cancer Treatment 2152
Radiation Fibrosis Syndrome 2152
Head and Neck Cancer 2156
Lymphedema 2158
Rehabilitation Interventions 2159
Nonpharmacologic Pain Management 2160

SECTION 2. COMPLEMENTARY, ALTERNATIVE, AND INTEGRATIVE THERAPIES

153. Complementary, Alternative, and Integrative Therapies in Cancer Care 2163

Catherine E. Ulbricht

Background 2163
Establishing an Integrative Oncology Approach with Patients 2163
Standardization and Quality 2166
Specific Complementary and Alternative Medicine Therapies 2166

Index 2175